CGON
CG Oncology, Inc.
$70.36
-0.53 (-0.75%)
At close · Jul 2
Market Cap
$6.21B
Shares
88,202,473
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$70.36
Open$71.13
Day$68.75–71.88
52W$23.65–76.60
Avg vol 30d1.0M
Short int10.6M · 12.0% float · 11.6d
Short vol54%
Last earningsMay 8, 2026
DataJan 2024–Jul 2026
Filing10-Q · May 8
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Strong Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+31% above
+
Price vs 50-day avg
+9% above
◦
RSI (14)
63 · neutral
+
MACD trend
positive
+
52-week position
88% · near high
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $65 › 200d $54 — 50d above 200d
−
Institutional flow
4 of 237 funds reported for Jun 30 · net -126 sh shares
−
Insider flow
Net -$1.2M over 90 days · 100% sells
−
Short interest
11.97% of float · ▲ +7.6% MoM · 11.6 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
237 holders — near 2-yr high, broad support
Fundamentals
Weak
−
EPS growth
−48% Y/Y
−
Free cash flow
$-132.5M
+
Balance sheet
net cash $32.5M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 9, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+31% above
Bullish
Price vs 50-day avg
+9% above
Bullish
RSI (14)
63 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
88% · near high
Bullish
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $65 › 200d $54 — 50d above 200d
Institutional flow
Distributing
4 of 237 funds reported for Jun 30 · net -126 sh shares
Insider flow
Distributing
Net -$1.2M over 90 days · 100% sells
Short interest
Rising
11.97% of float · ▲ +7.6% MoM · 11.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
237 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $24
Now $70 · 88%
52-wk high $77
vs 200-day avg +31%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CGON
this stock
CG Oncology, Inc.
|
$6.21B | +69.5% | — | — | 12.0% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CGON | -3.4% | +29.3% | +67.8% | -1.0% | +69.5% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -4.8% | +30.5% | +59.8% | -0.7% | +60.2% |